After having been relatively quiet on the deal making front for some time, AstraZeneca recently established three noteworthy research partnerships with AVANIR Pharmaceuticals, Astex Therapeutics and Schering. This feature considers AstraZeneca's rationale for entering into such agreements and why its early-stage partnering strategy is eminently sensible.